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H
epatitis C virus (HCV), discov-
ered almost 20 years ago, was 
resistant to being researched. 
Despite multiple attempts, researchers 
simply could not get this human pathogen 
to grow in culture. Lindenbach, as a young 
and enthusiastic graduate student had 
grand ideas about study-
ing HCV, but fearing a 
dead-end project for a 
PhD student, his supervi-
sor advised Lindenbach to 
work on the more willing 
yellow fever virus. The 
advice was wise; Linden-
bach passed his PhD, after 
making yellow fever yield 
the secret of how a secret-
ed protein could control 
viral replication inside the 
cell (1, 2).
Lured by the success, 
Lindenbach started a post-
doc studying other research-
friendly viruses. But his 
satisfaction was shallow, 
and the puzzle of how to grow HCV was   
continually on his mind.
In 2005, Lindenbach cracked the puz-
zle. He built a new, artifi  cial HCV (3) 
that could not only replicate in culture, 
but could also infect animals (4), proving 
that it was just like the real thing, only 
now researchable.
HIGH SCHOOL VIROLOGIST
When did you get interested in science?
I was interested in science at an early 
age, but both my parents were artists, so 
I didn’t have a lot of exposure to science. 
My dad encouraged my interest, because 
he thought it was diffi  cult to make a living 
as an artist—I don’t think he realized that 
science is just as hard! But also, I think it 
was a way for him to live the scientifi  c life 
vicariously—he had technical leanings. 
I actually became interested in viruses 
in middle school. I thought they were re-
ally cool. I remember reading a book that 
described the fi  rst genome ever sequenced. 
It was a small bacteriophage and its entire 
genome was written on half a page in the 
book. I thought to myself, “I can’t believe 
that this is everything that little virus 
needs.” It blew my mind.
Where did you go to college?
I went to the University of Illinois and 
majored in general biology. I was not sure 
what to do after college, but then I had a 
really great experience working as a tech 
in the laboratory of Ralph Wolfe. He stud-
ied archaebacteria, in particular methano-
gens, and I became fascinated. Not with 
methanogenesis per se, but with working 
in the laboratory. I decided I would go to 
graduate school and enrolled at Washing-
ton University in St. Louis. I studied for a 
PhD with Charlie Rice.
What was the focus of your PhD?
I wanted to study the interface between 
viruses and the immune system. Hepatitis 
C virus had just been discovered, and one 
of its major characteristics is that it causes 
chronic, persistent infections that are not 
cleared by the immune system. I thought 
that was a perfect topic.
But I didn’t realize how hard HCV 
would be to study. I had to switch topics, 
and started working on yellow fever virus. 
This was the fi  rst human virus to be dis-
covered, and there’s a vaccine for it, so 
I was able to work with the live virus.
HCV GIVES IT UP
You now work on HCV. So when did 
you switch back?
After my PhD, I went off to do a postdoc 
in Madison, Wisconsin, with Paul Ahl-
quist, who was studying the model posi-
tive strand RNA viruses: Flock House 
virus and brome mosaic virus. They’re re-
ally fantastic in that you can do all kinds 
of things with them that you can’t do with 
other viruses, but I missed studying medi-
cally important viruses. Right around this 
time, Ralph Bartenschlager’s group, who 
were working on HCV, made a break-
through by developing replicons—a sys-
tem for studying intracellular aspects of 
HCV replication.
Charlie had moved to Rockefeller 
[University] while I was in Madison, 
and he started working on these HCV 
replicons. He and I talked and decided 
that I should come back to his laboratory 
and work on developing the cell culture 
system further—the replicon system al-
lowed us to study intracellular viral repli-
cation, but not the entire viral life cycle.
How do replicons differ from the 
normal HCV?
Replicons are positive strand RNAs, like 
the full virus, but they only encode a sub-
set of the genes—the ones we think are 
important in RNA replication. They lack 
the structural genes that go on to make 
virus particles.
So what did you do with these replicons?
HCV has an extraordinary genetic diver-
sity because of its error-prone replication, 
and most replicons can replicate in culture 
because they accumulate adaptive muta-
tions. When I came back to Charlie’s lab-
oratory, we wanted to study full-length 
viruses in culture, but when we put the ex-
isting replicons into the full-length ge-
nome, we didn’t get viral production. We 
worked on the hypothesis that the adap-
tive mutations in the replicons were inhib-
iting virus production.
Lindenbach built a new hepatitis C virus to ﬁ  nd out how the wild one works. 
He plans to use this tool to understand the cell biology of virus–host interactions.
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Around this time, another laboratory 
described a replicon called JFH that didn’t 
need adaptive mutations to grow. We 
thought, “Aha, maybe if we make a full-
length genome out of this replicon, it will 
make an infectious virus.” So we contact-
ed the laboratory, they sent us the repli-
con, we reconstructed a full-length ge-
nome, and lo and behold, it produced virus 
particles. We went on to show that the re-
constructed virus was infectious in animals, 
so we knew it was bona fi  de.
Hang on, how does this reconstructed 
virus differ from the wild type?
That’s a really good question. The JFH 
replicon was derived from a virus that 
came from a Japanese patient with fulmi-
nant hepatitis (that’s where the name came 
from). But according to the researchers 
who derived the replicon, the original virus 
wouldn’t grow in culture. The JFH repli-
con seems to be an unusual isolate that rep-
licates without adaptive mutations.
Given HCV’s genetic diversity, I’m 
sure there are additional virus strains out 
there that will also effi  ciently replicate in 
culture, we just haven’t found them yet. 
So for the moment, reconstructed JFH 
strains are our best system for studying 
the complete life cycle of the virus.
So what have you learned about the 
virus’s life cycle, using this construct?
When we fi  rst grew the virus, we looked 
at its buoyant density, or how well it 
fl  oats, to learn about the basic physical 
properties of the virus. We found that 
HCV has two forms—a heavier form 
that’s not very infectious, and a light in-
fectious form. This form has an unusu-
ally low buoyant density, which is usu-
ally a sign that the virus is interacting 
with lipids.
Now we’re interested in understanding, 
what exactly is in these particles? How 
does it contribute to the infectivity of the 
virus? And how are the different virus par-
ticles made? We think that the more buoy-
ant form of virus might be coating itself 
with serum lipoproteins, to help mask it 
from the host immune response. But that’s 
still an emerging concept.
A SHORT FUTURE FOR HCV?
What are you working on these days?
Actually, the reason I came to Yale was 
because of its strength in microbiology 
and cell biology. I’m in a section called 
Microbial Pathogenesis—basically a cross 
between a microbiology and a cell biol-
ogy department. It’s a small group of 
people, all devoted to studying the host–
pathogen interaction at the cellular level, 
which has always been a strong interest 
of mine. So we’ve been doing some clas-
sical cell biological experiments to un-
derstand how virus particles are made.
We’re also getting into real-time imag-
ing of virus particles. And because we can 
manipulate the viral genome however we 
want, we can introduce tags that allow us 
to follow the viral proteins around.
By studying the virus–host interface, 
you end up learning more about each.
Oh, absolutely. I like to joke with some 
of my colleagues that cell biology is just 
a discipline of virology, because so many 
seminal fi  ndings had their origins in vi-
rology. May I remind you that the fi  rst 
article ever published in the Journal of 
Cell Biology was on imaging viruses?
In fact, some of the cellular pathways 
with which HCV interfaces are still 
poorly understood. For example, one of 
the small organelles in-
volved in HCV assembly 
is lipid droplets, which 
were thought to be inert 
balls of fat. It turns out 
that they’re actually dy-
namic structures that 
have all kinds of interest-
ing properties. So, I’m 
sure we’re going to learn 
more about lipid droplet 
biology, and other cell 
systems, as well as the 
virus itself.
Where do you see 
yourself in ten years?
In ten years I should hope that we aren’t 
working on HCV anymore, because it’ll 
no longer be a problem! 
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Lipid droplets (green) are sites of HCV (red) assembly. Lindenbach expects to learn more about 
both viruses and their host cells thanks to live cell imaging studies.
“May I 
remind you 
that the first 
article ever 
published in 
the Journal 
of Cell 
Biology was 
on imaging 
viruses?”